Peripheral nerve function and symptom distress during biotherapy for malignant melanoma

Constance G. Visovsky

Abstract


Studies of biotherapy-induced physiological changes are few, and systematic monitoring for neurotoxic effects are lacking. The purpose of this exploratory pilot study was to determine the change in peripheral nerve function and symptom distress during treatment with biotherapy for malignant melanoma. A convenience sample of 11 participants with malignant melanoma receiving interferon-alpha had measures of peripheral nerve function measured at baseline, four and 12 weeks of treatment. Data were analyzed using plots and regression slopes to determine change over time in sensation, gait/balance, vision, hearing, vibratory sense, muscle strength, deep tendon reflexes, blood pressure, and symptom distress. Declines in hearing, sensation, vibration, and muscle strength were found. Changes in visual acuity, and orthostatic blood pressure were noted, while gait/balance remained stable. Additionally, neuropathy symptoms were associated with symptom distress. The characterization of such changes can increase our understanding of the nature of the physiological effects associated with high-dose biotherapy treatment and aid clinicians to better prepare patients for anticipated changes in function and subsequent lifestyle adjustments. These findings can be used to provide information in a larger study of this phenomenon regarding important outcomes and measurement time-points of therapy-induced neuropathy and decreasing symptom distress in patients receiving cancer treatment with biologic agents.

Key words: peripheral neuropathy, biotherapy, clinical, measurement


Full Text:

PDF

References


American Cancer Society. (2003). Retrieved from:

http://www.cancer.org.

Armstrong, T., Rust, D., & Kohtz, J. (1997). Neurologic,

pulmonary and cutaneous toxicities of high-dose

chemotherapy. Oncology Nursing Forum Supplement, 24(1),

-33.

Belani, K., Ozaki, M., Hynson, J., Hartmann, T., Reyford, H.,

Martino, J.M., Poliac, M., & Miller, R. (1999). A new noninvasive

method to measure blood pressure: Results of a multicenter trial.

Anesthesiology, 91(3), 686-692.

Berger, T., Malayeri, R., Doippelbauer, A., Krajnik, G., Huber,

H., Auff, E., & Pirker, R. (1997). Neurological monitoring

of neurotoxicity induced by paclitaxel/cisplatin

chemotherapy. European Journal of Cancer, 33(9), 1393-

Birke, J., & Sims, D. (1985, December 16-18). Plantar sensory

threshold in the Hansen’s disease ulcerated foot.

Proceedings of the International Conference on

Biomechanics and Clinical Kinesiology of Hand and Foot,

Madras, India.

Bohannon, R., & Andrews, A. (1987). Interrater reliability of handheld

dynamometry. Physical Therapy, 67, 931-933.

Bouldin, T. (1994). The peripheral nervous system. In Rubin & Farber

(Eds.), Pathology (pp 1447-1455). Philadelphia: J.B. Lippincott

Company.

Bradley, A., Hook, J., & Haeseker, J. (1991). A comparison of

clinical acuity and contrast sensitivity charts: effect of

uncorrected myopia. Ophthalmic Physiology, 11(3), 218-

Canadian Cancer Society, (2004). Canadian Cancer Statistics.

Retrieved from: http://www.cancer.ca/ccs/internet/standard/

,3182,3172_14279__langId-en,00.html

Fattovich, G., Giustina, G., Favarato, S., Ruol, A., et al. (1996). A

survey of adverse events in 11,241 patients with chronic viral

hepatitis treated with alpha interferon. Journal of Hepatology, 24,

-47.

Gastineau, D., Habermann, T., & Hermann, R. (1989). Severe

neuropathy associated with low-dose recombinant interferonalpha.

American Journal of Medicine, 87,116.

Gotaskie, G., & Andreassi, B. (1994). Paclitaxel: A new

antimitotic chemotherapeutic agent. Cancer Practice, 2(4),

-33.

Haapaniemi, J.J., Suonpaa, J.T, Salmivalli, A.J. & Virolainen, E.S.

(1996). C1-tuning fork tests in school-aged children. Auris Nasus

Larynx, 23, 26-32.

Irwin, M. (1987). Patients receiving biologic response modifiers:

Overview of nursing care. Oncology Nursing Forum, 14(6), 32-

Klima, R., Weigand, A., & DeLisa, J. (1991). Nerve conduction

studies and vibration perception thresholds in diabetic and uremic

neuropathy. American Journal of Physical and Medical

Rehabilitation, 70(2), 86.

Manesis, E., Petrou, C., Brouzas, D., & Hadziyannis, S. (1994). Optic

tract neuropathy complicating low-dose interferon treatment.

Journal of Hepatology, 21, 474-477.

Merriggioli, M., & Brown, J. (2000). Chronic inflammatory

demyelinating polyneuropathy after treatment with interferonalpha.

Muscle & Nerve, 23, 433-435.

Meyers, C., Scheibel, R., & Forman, A. (1991). Persistent

neurotoxicity of systematically administered Interferon-Alpha.

Neurology, 41, 672-676.

Miltenburg, D.M. (1994). The validity of tuning fork tests in

diagnosing hearing loss. Journal of Otolaryngology, 23(4), 254-

Postma, T., Hoekman, K., van Riel, J.M.G.H., Heimans, J.J., &

Vermorken, J.B. (1999). Peripheral neuropathy due to

biweekly paclitaxel, epirubicin and cisplatin in patients with

advanced ovarian cancer. Journal of Neuro-Oncology, 45,

-246.

Postma, T., & Heimans, J. (2000). Grading of chemotherapyinduced

peripheral neuropathy. Annals of Oncology, 11, 509-

Quaal, S. (1997). Measuring cardiac parameters. In Frank-Stromborg

& Olsen (Eds.), Instruments for clinical health-care research

(pp. 445-458).

Quattrini, A., Comi, G., Nemni, R., Martinelli, V., Villa, A.,

Caimi, et al. (1997). Axonal neuropathy associated with

interferon-alpha treatment for hepatitis C: HLA-DR

immunoreactivity in Schwann cells. Acta Neuropathologica,

, 504-508.

Rendell, M., Katims, J., & Richter, R. (1989). A comparison of

nerve conduction velocities and current perception thresholds

as correlates of clinical severity of diabetic sensory neuropathy.

Journal of Neurology and Neurosurgical Psychiatry, 52,

Rhodes, V., McDaniel, R., Homan, S.H., Johnson, M., & Madsen, R.

(2000). An instrument to measure symptom experience. Cancer

Nursing, 23(1), 49-54.

Smith, J., Longo, D., Urba, W., Clark, J., Watson, T., Beveridge, J., et

al. (1991). Prolonged, continuous treatment of hairy cell leukemia

patients with recombinant interferon-alpha 2A. Blood, 78(7),

-1671.

Spellbring, A., & Ryan, J. (1997). Measuring mobility and potential

for falls. In Frank-Stromborg & Olsen (Eds.), Instruments for

health-care research (pp.497-508).

Tinetti, M. (1986). Performance-oriented assessment of mobility

problems in elderly patients. Journal of the American Geriatric

Society, 34, 119-126.

Vial, T., & Descotes, J. (1994). Clinical toxicity of the interferons.

Drug Safety, 10(2), 115-150.

Visovsky, C. (2003). Chemotherapy-induced peripheral neuropathy.

Cancer Investigation, 21(3), 439-451.

Wilkes, G. (1996). Neurological disturbances. In Groenwald, Frogge,

Goodman & Yarbro (Eds.), Cancer symptom management (pp.

-355). Boston: Jones & Bartlett.


Refbacks

  • There are currently no refbacks.


Bookmark and Share